CHS-114

Phase 1Small molecule

CCoherus Oncology, Inc.

CHS-114 is one of 45 small molecule programs targeting Solid Tumor. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Solid TumorActive, not recruiting

Metastatic Solid TumorRecruiting

Solid TumorPhase 1

Active, not recruiting

Metastatic Solid TumorPhase 1

Recruiting

Competition

Competitive Landscape

348 competitors in Solid Tumor

#DrugCompanyPhaseTrials

Yervoy

Bristol-Myers Squibb

Preclinical

3 2

Fludara

Sanofi

Preclinical

2 3

Nubeqa

Bayer

Preclinical

2 4

DATROWAY

Daiichi Sankyo

Preclinical

1 5

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

3 6

Zejula

GGlaxo Dba Glaxosmithkline

Preclinical

2 7

Augtyro

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

2 8

Paxil

SSebela Pharmaceuticals Development LLC

Preclinical

1 9

Tulmimetostat

Novartis

Preclinical

1 10

Chemotherapy Drug

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Active, not recruiting

Solid Tumor

NCT05635643

Q1 2028

Phase 1Recruiting

Metastatic Solid Tumor

NCT06657144

Clinical

Trials by Indication[1]

Solid Tumor1 trial

A Phase 1 Study of CHS-114 in Participants With Advanced Solid Tumors

Active, not recruiting·CCoherus Oncology, Inc.·Phase 1·NCT05635643·87 enrolled

Metastatic Solid Tumor1 trial

A Phase 1B, Multicenter, Open-Label Study of the Safety and Efficacy of CHS-114 in Combination With Toripalimab With or Without Other Treatments in Participants With Advanced or Metastatic Solid Tumors (TREGCHECK 102)

Recruiting·CCoherus Oncology, Inc.·Phase 1·NCT06657144·154 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for CHS-114. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CHS-114 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CHS-114. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Coherus Oncology, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: CCoherus Oncology, Inc.

CHS-114

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q1 2028

Trials by Indication[1]

Solid Tumor1 trial

Metastatic Solid Tumor1 trial

References

Drug Info

Quick Facts

Related News